Trading Halt
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Vitrafy Life Sciences Limited has requested a trading halt for its securities pending an announcement regarding a proposed equity capital raising. The halt will remain in effect until the earlier of the announcement's release or the commencement of normal trading on a specified date. This request aims to manage disclosure obligations and ensure informed trading in the market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-1618
Vitrafy Life Sciences Ltd. on 6ix
In the deck
Earlier from Vitrafy Life Sciences
- Vitrafy enters a partnership with Vitalant Innovation Center
- Phase 2 USAISR Platelet Results Investor Presentation
- Final US Army Phase 2 Platelet Results
- Q3 FY26 Quarterly Activities Report and Appendix 4C
- USAISR Completes Phase 2 Platelet Study
Later from Vitrafy Life Sciences
- Vitrafy Equity Raising Presentation
- Vitrafy Placement Completion and SPP Announcement
- Vitrafy Share Purchase Plan Opens - SPP Offer Booklet
- Vitrafy enters a partnership with Hoxworth Blood Center
- Q4 FY26 Quarterly Activities Report and Appendix 4C
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences